Generic Tygacil Availability
TYGACIL (tigecycline - injectable;iv (infusion))
Manufacturer: PF PRISM CV
Approval date: June 15, 2005
Strength(s): 50MG/VIAL [RLD]
Has a generic version of Tygacil been approved?
No. There is currently no therapeutically equivalent version of Tygacil available in the United States.
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Tygacil. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: About generic drugs.
Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.
Tigecycline compositions and methods of preparation
Issued: February 1, 2011
Inventor(s): Fawzi; Mahdi B. & Zhu; Tianmin & Shah; Syed M.
Assignee(s): Wyeth LLC
The present invention relates to novel tigecycline compositions with improved stability in both solid and solution states and processes for making these compositions. These compositions comprise tigecycline, a suitable carbohydrate, and an acid or buffer.Patent expiration dates:
- February 5, 2029✓
- February 5, 2029
Crystalline solid forms of tigecycline and methods of preparing same
Issued: February 12, 2013
Assignee(s): Wyeth LLC
Crystalline solid forms of tigecycline, Form I, Form II, Form III, Form IV, and Form V, compositions comprising these crystalline solid forms, and processes for preparing these crystalline solid forms are described herein.Patent expiration dates:
- October 8, 2030✓
- October 8, 2030
Issued: March 25, 2008
Inventor(s): Hlavka; Joseph J. & Sum; Phaik-Eng & Gluzman; Yakov & Lee; Ving J. & Ross; Adma A.
Assignee(s): Wyeth Holdings Corporation
The invention is drawn to 7-substituted-9-(substituted amino)-6-demethyl-6-deoxytetracycline compounds of the formula wherein R, X, R5 and R6 are defined in the specification. The compounds of the invention are useful as broad spectrum antibiotics.Patent expiration dates:
- April 9, 2016✓✓
- April 9, 2016
- Tygacil Consumer Information (Drugs.com)
- Tygacil Consumer Information (Wolters Kluwer)
- Tygacil Consumer Information (Cerner Multum)
- Tygacil Advanced Consumer Information (Micromedex)
- Tygacil AHFS DI Monographs (ASHP)
- Tigecycline Consumer Information (Wolters Kluwer)
- Tigecycline Consumer Information (Cerner Multum)
- Tigecycline Intravenous Advanced Consumer Information (Micromedex)
- Tigecycline AHFS DI Monographs (ASHP)
|Drug Patent||A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation.|
|Drug Exclusivity||Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant.|
|RLD||A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart.|